
CSTL Stock Forecast & Price Target
CSTL Analyst Ratings
Bulls say
Castle Biosciences Inc. has demonstrated remarkable growth in its TissueCypher test, with test volumes increasing 92% year-over-year and 23% quarter-over-quarter in 2Q25, indicative of strong market demand and effective sales force expansion. The company's strategic moves have led to improved gross margins for TissueCypher, achieving an impressive 77% in Q3, which underscores its operational efficiency and profitability. Additionally, the anticipated maturation of the gastrointestinal sales force in the latter half of 2025 further supports a positive growth trajectory for the company's diagnostics portfolio.
Bears say
Castle Biosciences Inc. faces a negative outlook due to concerns over the revenue generation potential of its primary tests, specifically the DecisionDx-Melanoma, in comparison to its TissueCypher product, with expectations that EV-to-estimated 2026/2027 revenue multiples for dermatology and DecisionDx-UM tests will be substantially lower. Additionally, management's acknowledgment of significant clinician unawareness regarding the tests indicates a substantial barrier to market penetration, impacting revenue growth prospects. Despite indications that the stock may appear undervalued based on conservative estimates, these fundamentals suggest a challenging environment for sustained financial performance.
This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
CSTL Analyst Forecast & Price Prediction
Start investing in CSTL
Order type
Buy in
Order amount
Est. shares
0 shares